|1.||Ordóñez, Nelson G: 5 articles (03/2006 - 08/2003)|
|2.||Klimstra, David S: 4 articles (10/2014 - 09/2010)|
|3.||Katabi, Nora: 2 articles (10/2014 - 11/2012)|
|4.||Terada, Tadashi: 2 articles (05/2014 - 12/2010)|
|5.||Chen, Xiuqin: 2 articles (11/2013 - 01/2013)|
|6.||Baranowska-Kortylewicz, Janina: 2 articles (09/2005 - 07/2002)|
|7.||Enke, Charles A: 2 articles (09/2005 - 07/2002)|
|8.||Kurizaki, Takashi: 2 articles (09/2005 - 07/2002)|
|9.||Artiko, V: 2 articles (07/2003 - 01/2003)|
|10.||Adanja, G: 2 articles (07/2003 - 01/2003)|
04/01/1988 - "These results thus demonstrate the efficacy of i.v. and i.p.-administered MAb B72.3 for the radiolocalization as well as potential use of MAb B72.3 in protocols aimed at tumor targeting and in MAb-guided therapy for human epithelial malignancies."
02/01/2011 - "A humanized and CH2 domain-deleted CC49 antibody radiolabeled with (111)In/(90)Y showed improved tumor-to-normal dose ratios over those reported from studies with intact CC49."
02/01/1995 - "The tumors yielded positive results in 23/23, 22/23, 17/23, 22/23, and 18/23 cases when stained with Cam 5.2, AE1/AE3, Leu M-1, CEA, and B72.3, respectively. "
12/01/2005 - "The current study was designed to systematically document the cytomorphology of gastric and duodenal epithelium on fixed and air-dried smears, as well as ThinPrep (TP) preparations, and to assess the reactivity of the epithelial cells to the tumor marker B72.3 so as to establish a baseline for future comparative studies with EUS-FNAB of the pancreas. "
09/01/2005 - "These effects were dose-dependent and under optimized dosing conditions allowed for a 2.45 times increase in the tumor uptake of B72.3 as determined in the biodistribution studies. "
|2.||Colorectal Neoplasms (Colorectal Cancer)
05/01/1996 - "In a blinded fashion, radiolabeled B72.3 was investigated in operative cases of recurrent colorectal cancer to determine if diagnostic accuracy would be improved to ultimately maximize curability and minimize interventional morbidities. "
06/01/1987 - "Previous studies have demonstrated that radioiodinated B72.3 can selectively bind to human colorectal carcinomas grown in athymic mice. "
04/01/1998 - "Localization of colorectal carcinoma by rhenium-188-labeled B72.3 antibody in xenografted mice."
02/01/1994 - "Immunoscintigraphy of primary colorectal cancers with indium-111 monoclonal antibody B72.3."
01/01/1994 - "We conclude that mAb CC49 has better relative uptake in colorectal cancers than mAb B72.3."
10/15/1993 - "However, the distribution of B72.3 reactivity in adenocarcinomas has not been well-enough defined to determine whether B72.3 immunostaining would be helpful in the diagnosis of adenocarcinoma of unknown origin. "
09/01/1993 - "Future prospective studies comparing CT scans, CEA estimation and B72.3 radioimmunoscintigraphy in a larger group of patients with suspected residual or recurrent colorectal adenocarcinoma may help to define the respective sensitivity and specificity of these techniques."
04/01/1985 - "In this preliminary study, we report that MAb B72.3 may be used as an adjunct for diagnosis of adenocarcinoma in cytological preparations of human effusions. "
05/01/2010 - "B72.3 was positive in 95% of adenocarcinomas and 85% of mucinous lesions. "
07/01/2002 - "Athymic mice xenografted with human colorectal adenocarcinoma LS174T were treated intravenously with low doses (9.25 MBq) of 131I-labeled mAb B72.3 in combination with various intravenous doses of AP. "
07/01/1999 - "To assess the efficacy of monoclonal antibody (MoAb) B72.3 for in vivo-immunoscintigraphy of pancreatic carcinoma in nude mice. "
01/01/1998 - "In this article, we present a retrospective review of 136 patients from 10 moderate-sized hospitals who underwent a study with radioimmunoscintigraphy (RIS), using the 111In B72.3 antibody and standard diagnostic examinations for the detection of recurrent colorectal or ovarian carcinoma. "
06/02/1989 - "MAb B72.3 has been shown to exhibit a high degree of selective reactivity with colon, breast and ovarian carcinomas and has been used for radioimmunodiagnosis in model systems and in clinical trials. "
07/01/1988 - "These studies indicate the potential utility of MAb B72.3 in the diagnosis of gynecologic carcinoma."
10/01/2014 - "MUC1, CEA, and B72.3 were positive only in carcinoma. "
|5.||Neoplasm Metastasis (Metastasis)
01/01/2002 - "Interestingly, MAb B72.3 was significantly expressed in a subgroup of patients characterised by larger tumour size (p=0.013), lymph node metastasis (p=0.0002), high histopathological grade (p=0.006), high cell kinetics (p=0.04) and advanced clinical stage (p=0.0019). "
07/01/1999 - "BerEP4 and B72.3 appear to be the best markers when both sensitivity and specificity are considered, followed by BG8, while CEA and CA-125 have a limited role in the detection of metastases from gynaecological tumours owing to the low sensitivity of the former and the low specificity of the latter. "
12/01/1996 - "In lymph node metastases, immunoreactivity was found for c-erb B-2 protein in 36.4% of cases (12 of 33), for B72.3 in 63.7% of cases (21 of 33), and for CEA in 24.3% of cases (8 of 33). "
04/01/1995 - "Stromal type for TKH2, B72.3, CA19-9 and CEA were seen in 14 (50%), 13 (46%), 18 (64%) and nine (32%) cases with peritoneal dissemination, respectively, and in four (17%), three (13%), four (17%) and four (17%) cases with liver metastasis, respectively. "
01/01/1985 - "There was a statistically significant positive correlation between MAb B72.3 reactivity in both primary and lymph node metastases (Kendall's Correlation Coefficient = 0.60, p = 0.0006) and between lymph node and distant metastases (Kendall's Correlation Coefficient = 0.48, p = 0.02) of the same patient. "
|1.||Immunoglobulin G (IgG)
|2.||monoclonal antibody FO23C5
|4.||Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)
|8.||tumor-associated antigen 72
|1.||Heterologous Transplantation (Xenotransplantation)
|5.||Drug Therapy (Chemotherapy)